Study to Test Software Algorithm for Insulin Therapy and New Glucose Sensor
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female aged 18 to 75 years (both inclusive)
Informed consent obtained after being advised of the nature of the study
The subject has Type 1 diabetes (as defined by WHO) for at least 24 months
The subject's HbA1c <= 10%
Body Mass Index (BMI) <= 35 kg/m2
The subject is treated with continuous subcutaneous insulin infusion for at least 3 month
Subject is actively enrolled in another clinical trial or took part in a study within 30 days
Experienced recurrent severe hypoglycaemic unawareness
Total daily insulin dose >= 1.4 IU/kg
Subject is using a medication that significantly impacts glucose metabolism (oral or topical steroids) except if stable for at least the last three months and expected to remain stable for the study duration
Allergy against insulin Lispro
A history of drug or alcohol dependence
Any other significant concomitant disease such as endocrine, cardiac, neurological, malignant, other pancreatic disease or uncontrolled hypertension as judged by the investigator
Uncontrolled hypertension with resting blood pressure over 140/90 mmHg
Patient is pregnant, or breast feeding during the period of the study